Intellia Therapeutics (NTLA) Competitors $10.72 -0.02 (-0.14%) Closing price 07/3/2025 03:59 PM EasternExtended Trading$10.66 -0.06 (-0.56%) As of 07/3/2025 04:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock NTLA vs. BEAM, CRSP, EDIT, ZLAB, PTCT, MRUS, ACLX, ACAD, SWTX, and RAREShould you be buying Intellia Therapeutics stock or one of its competitors? The main competitors of Intellia Therapeutics include Beam Therapeutics (BEAM), CRISPR Therapeutics (CRSP), Editas Medicine (EDIT), Zai Lab (ZLAB), PTC Therapeutics (PTCT), Merus (MRUS), Arcellx (ACLX), ACADIA Pharmaceuticals (ACAD), SpringWorks Therapeutics (SWTX), and Ultragenyx Pharmaceutical (RARE). These companies are all part of the "med - biomed/gene" industry. Intellia Therapeutics vs. Its Competitors Beam Therapeutics CRISPR Therapeutics Editas Medicine Zai Lab PTC Therapeutics Merus Arcellx ACADIA Pharmaceuticals SpringWorks Therapeutics Ultragenyx Pharmaceutical Beam Therapeutics (NASDAQ:BEAM) and Intellia Therapeutics (NASDAQ:NTLA) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, risk, dividends, valuation, institutional ownership, profitability, earnings and analyst recommendations. Do insiders & institutionals believe in BEAM or NTLA? 99.7% of Beam Therapeutics shares are owned by institutional investors. Comparatively, 88.8% of Intellia Therapeutics shares are owned by institutional investors. 3.5% of Beam Therapeutics shares are owned by company insiders. Comparatively, 3.1% of Intellia Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Does the media favor BEAM or NTLA? In the previous week, Intellia Therapeutics had 5 more articles in the media than Beam Therapeutics. MarketBeat recorded 12 mentions for Intellia Therapeutics and 7 mentions for Beam Therapeutics. Beam Therapeutics' average media sentiment score of 0.77 beat Intellia Therapeutics' score of 0.37 indicating that Beam Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Beam Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Intellia Therapeutics 6 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is BEAM or NTLA more profitable? Beam Therapeutics has a net margin of -609.24% compared to Intellia Therapeutics' net margin of -1,154.10%. Beam Therapeutics' return on equity of -44.24% beat Intellia Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Beam Therapeutics-609.24% -44.24% -30.97% Intellia Therapeutics -1,154.10%-56.06%-44.25% Which has higher valuation & earnings, BEAM or NTLA? Beam Therapeutics has higher revenue and earnings than Intellia Therapeutics. Beam Therapeutics is trading at a lower price-to-earnings ratio than Intellia Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBeam Therapeutics$63.52M31.69-$376.74M-$4.61-4.34Intellia Therapeutics$57.88M19.18-$519.02M-$5.23-2.05 Which has more risk and volatility, BEAM or NTLA? Beam Therapeutics has a beta of 2.07, suggesting that its stock price is 107% more volatile than the S&P 500. Comparatively, Intellia Therapeutics has a beta of 2.21, suggesting that its stock price is 121% more volatile than the S&P 500. Do analysts recommend BEAM or NTLA? Beam Therapeutics presently has a consensus price target of $48.75, indicating a potential upside of 143.51%. Intellia Therapeutics has a consensus price target of $33.37, indicating a potential upside of 211.42%. Given Intellia Therapeutics' higher probable upside, analysts plainly believe Intellia Therapeutics is more favorable than Beam Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Beam Therapeutics 0 Sell rating(s) 2 Hold rating(s) 11 Buy rating(s) 2 Strong Buy rating(s) 3.00Intellia Therapeutics 1 Sell rating(s) 6 Hold rating(s) 12 Buy rating(s) 1 Strong Buy rating(s) 2.65 SummaryBeam Therapeutics beats Intellia Therapeutics on 12 of the 17 factors compared between the two stocks. Get Intellia Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NTLA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NTLA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NTLA vs. The Competition Export to ExcelMetricIntellia TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.11B$2.91B$5.53B$8.95BDividend YieldN/A2.42%5.38%4.09%P/E Ratio-2.0521.5627.4020.24Price / Sales19.18277.33417.66125.07Price / CashN/A41.9536.6357.47Price / Book1.257.518.085.67Net Income-$519.02M-$55.05M$3.16B$248.47M7 Day Performance12.08%4.59%2.81%3.29%1 Month Performance39.70%4.86%3.69%5.18%1 Year Performance-53.31%5.82%35.30%21.35% Intellia Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NTLAIntellia Therapeutics4.652 of 5 stars$10.72-0.1%$33.37+211.4%-53.3%$1.11B$57.88M-2.05600News CoverageBEAMBeam Therapeutics2.407 of 5 stars$17.01+1.3%$48.75+186.6%-14.7%$1.71B$63.52M-3.69510CRSPCRISPR Therapeutics3.0495 of 5 stars$48.64+2.4%$71.75+47.5%-3.2%$4.20B$35M-10.76473High Trading VolumeEDITEditas Medicine4.3875 of 5 stars$2.20-3.5%$4.70+113.6%-44.5%$184.17M$35.84M-0.72230Gap UpZLABZai Lab3.4351 of 5 stars$34.97+0.7%$54.28+55.2%+111.6%$3.88B$398.99M-14.041,869Insider TradeAnalyst RevisionGap UpPTCTPTC Therapeutics4.3337 of 5 stars$48.84-2.0%$65.00+33.1%+57.3%$3.87B$1.77B7.501,410Analyst RevisionMRUSMerus1.4892 of 5 stars$52.60-0.7%$84.64+60.9%+1.7%$3.64B$54.73M-12.8937ACLXArcellx3.0009 of 5 stars$65.85+0.8%$111.23+68.9%+23.0%$3.63B$107.94M-22.0280ACADACADIA Pharmaceuticals4.7016 of 5 stars$21.57-2.5%$27.88+29.2%+34.4%$3.61B$996.28M15.74510SWTXSpringWorks Therapeutics1.7161 of 5 stars$46.99+0.0%$52.57+11.9%N/A$3.54B$191.59M-13.78230RAREUltragenyx Pharmaceutical4.1687 of 5 stars$36.36-0.4%$87.00+139.3%-2.5%$3.44B$590.69M-6.181,294 Related Companies and Tools Related Companies Beam Therapeutics Alternatives CRISPR Therapeutics Alternatives Editas Medicine Alternatives Zai Lab Alternatives PTC Therapeutics Alternatives Merus Alternatives Arcellx Alternatives ACADIA Pharmaceuticals Alternatives SpringWorks Therapeutics Alternatives Ultragenyx Pharmaceutical Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NTLA) was last updated on 7/4/2025 by MarketBeat.com Staff From Our Partners379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | Sponsored“E.I.”- The biggest prediction of my career?One expert predicts that E.I. could see over 200,000% growth... But you need to move fast...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Intellia Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Intellia Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NTLA Stock Alerts